Atlas Trials

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Clinical trial NCT06564298 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06564298
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Stomach Neoplasms
Start date
2024-08-01
Primary completion
2025-12-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.